Caissa Capital Management ltd., 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 26,621 shares at $3.52 ($89K) on 2023-05-19, disclosed to the SEC on 2023-05-22.
Open-market purchase of $89k AVTX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.29 | 13,121 | $43K | 48.3% |
| 2 | $3.52 | 6,500 | $23K | 25.6% |
| 3 | $3.34 | 7,000 | $23K | 26.1% |
| Total | $3.36 avg | 26,621 | $89K | 100% |
| Filing → |
| AVTX | BUY | 2023-06-14 | $64K | — | Filing → |
| AVTX | BUY | 2023-06-09 | $56K | — | Filing → |
| AVTX | BUY | 2023-06-02 | $2K | — | Filing → |